



SR0018

LRB103 25958 MST 52310 r

1

SENATE RESOLUTION

2 WHEREAS, The substance use and opioid use crises in
3 Illinois are responsible for historically high rates of
4 overdoses and overdose-related fatalities; and

5 WHEREAS, According to the State's own opioid data, use and
6 misuse of opioids in Illinois also continues to have
7 substantial associated public health consequences, including
8 increased rates of infectious diseases such as hepatitis C and
9 HIV, lost productivity in the workplace, crime, neonatal
10 abstinence syndrome, and homelessness; and

11 WHEREAS, The purpose of many federal programs is to
12 provide resources to states for increasing access to
13 FDA-approved medications for the treatment of substance use
14 and opioid use disorder and for supporting the continuum of
15 prevention, harm reduction, treatment, and recovery support
16 services for opioid use disorder and other substance use
17 disorders; and

18 WHEREAS, A prescription digital therapeutic is approved,
19 cleared, or classified by the Food and Drug Administration
20 under section 510(k), 513(f), or 515 of the Federal Food,
21 Drug, and Cosmetic Act, and requires a prescription under
22 section 801.109 of title 21 of the Code of Federal Regulations

1 (or any successor regulation); and

2 WHEREAS, Prescription digital therapeutics have the
3 potential to significantly improve health care delivery to
4 underserved populations because they transcend care access
5 limitations due to geography, socioeconomic status, trust of
6 traditional institutions, and more; and

7 WHEREAS, Clinical studies have shown significantly greater
8 odds of stimulant and opioid abstinence during treatment if
9 treatment as usual is combined with an FDA-authorized PDT that
10 has both cognitive behavioral therapy and contingency
11 management; and

12 WHEREAS, A 2018 study demonstrated that when a Community
13 Reinforcement Approach and Contingency Management are
14 administered together then a patient is 2.84 times more likely
15 to remain abstinent at the end of the treatment than those in
16 other programs; and

17 WHEREAS, The White House's Office of National Drug Control
18 Policy recently released its 2022 National Drug Control
19 Strategy document; specifically, the document points to
20 prescription digital therapeutics and how these tools could
21 help increase services for a wide array of patients; and

1 WHEREAS, Federally-funded programs help many states to
2 fund access to FDA-authorized PDTs for patients and providers;
3 therefore, be it

4 RESOLVED, BY THE SENATE OF THE ONE HUNDRED THIRD GENERAL
5 ASSEMBLY OF THE STATE OF ILLINOIS, that we urge the Department
6 of Human Services and the Governor's Opioid Overdose
7 Prevention and Recovery Steering Committee to closely consider
8 funding FDA-authorized PDTs to help patients who are
9 struggling with substance use and opioid use disorders; and be
10 it further

11 RESOLVED, That a suitable copy of this resolution be
12 delivered to the Secretary of the Illinois Department of Human
13 Services.